Patents and Trademarks
Acura actively pursues patents and trademark protection for our business interests. Except for those rights conferred in the Pfizer Agreement, Acura has retained all intellectual property rights to our technologies and related product candidates. We encourage you to refer to the Risk Factors link on this web site and contained in our filings with the Securities and Exchange Commission for a discussion of, among other things, the effect pending patent applications owned by third parties would have on our business if issued.
Issued Patents
| Patent Number | Jurisdiction | Allowed Claims | General Subject |
|---|---|---|---|
| 7,201,920 | U.S. | 54 | Compositions including an opioid intended to deter the most common methods of prescription opioid analgesic product misuse and abuse. We believe the 920 Patent encompasses all of our opioid analgesic product candidates currently in development. This patent does not require niacin to be a constituent of a product for the product to be within the scope of the patent claims. |
| 7,510,726 | U.S. | 20 | Compositions including an opioid and an expanded list (compared to the 920 Patent) of functional inactive ingredients intended to deter the most common methods of prescription opioid analgesic product misuse and abuse. This patent does not require niacin to be a constituent of a product for the product to be within the scope of the patent claims. |
| 7,981,439 | U.S. | 7 | Compositions including any water soluble drug of abuse intended to deter the most common methods of prescription opioid analgesic product misuse and abuse. We believe our stimulant and benzodiazepine product candidates currently in development are encompassed by the 439 Patent. |
| 7,476,402 | U.S. | 18 | Compositions including kappa and mu opioid receptor agonists intended to deter opioid analgesic product misuse and abuse. |
Pending Patents
In addition to our issued U.S. Patents, we have filed multiple U.S. patent applications and international patent applications relating to compositions containing abusable active pharmaceutical ingredients as well as applications covering our Impede Technology. Except for those rights conferred in the Pfizer Agreement, we have retained all intellectual property rights to our Aversion Technology, Impede Technology, and related product candidates.
Reference is made to the Risk Factors contained in Item 1A of Part II of our Report on Form 10-Q for the quarter ended June 30, 2011 for a discussion, among other things, of patent applications and patents owned by third parties including claims that may encompass our Aversion Technology and Oxecta Tablets.
Trademarks
Acura Pharmaceuticals®, Aversion®, Acurox®, Vycavert®, Prazavert®, Tramavert®, and Acuracet® are registered trademarks of Acura Pharmaceuticals, Inc.
Impede™ and Nexafed™ are trademarks of Acura Pharmaceuticals, Inc.
Oxecta® is a registered trademark of Pfizer, Inc.
